t(8;21)(q22;q22) RUNX1/RUNX1T1 in treatment related leukemia
2003-10-01 Jean-Loup Huret Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
Treatment related myelodysplasia (t-MDS) or acute myeloid leukaemias (t-AML)
Note
The study included 44 cases; t-MDS with or without progression to AML accounted for 20% and t-AML for the remaining 80%; no case of acute lymphoblastic leukaemia
Epidemiology
t(8;21)(q22;q22) was found in 9% of t-MDS/t-AML; 1M to 1F sex ratio
Clinics
Age at diagnosis of the primary disease 45 yrs (range 2-75); age at diagnosis of the t-MDS/t-AML: 47 yrs for patients with the t(8;21) solely and 50 yrs for patients with an additional anomaly; range was(15-77). Median interval was 39 mths for cases with t(8;21) solely, and 33 mths in other cases; (range: 6-306). Primary disease was a solid tumor in 70% of cases ( breast cancer in particular) and a hematologic malignancy in 30%, treated with radiotherapy (12%), chemotherapy (42%), or both (46%).
Cytology
Cell morphology was similar to those of de novo t(8;21)
Prognosis
Median survival was 17mths and 31 mths respectively for patients without and with additionnal anomalies, but the difference was not significant. Outcome was better than the outcome of patients with 11q23 rearrangement, 3q21q26 rearrangement, 12p13 rearrangement, t(9;22), t(8;16), or a t(3;21) and worse than the outcome of patients with with t(15;17) or inv(16) treatment related leukemias.
Genes Involved and Proteins
Result of the Chromosomal Anomaly
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 34945003 | 2021 | PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. | 242 |
| 35065680 | 2022 | Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. | 172 |
| 31817911 | 2019 | Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription. | 150 |
| 36068610 | 2022 | ASXL1/2 mutations and myeloid malignancies. | 129 |
| 38061017 | 2023 | Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein. | 112 |
| 36980682 | 2023 | Deregulated Gene Expression Profiles and Regulatory Networks in Adult and Pediatric RUNX1/RUNX1T1-Positive AML Patients. | 103 |
| 31935293 | 2020 | An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. | 101 |
| 39177514 | 2024 | Mutational cooperativity of RUNX1::RUNX1T1 isoform 9a and oncogenic NRAS in zebrafish myeloid leukaemia. | 96 |
| 33928020 | 2021 | Characteristics of Cohesin Mutation in Acute Myeloid Leukemia and Its Clinical Significance. | 87 |
| 36874378 | 2023 | Therapy-related core binding factor acute myeloid leukemia. | 86 |
| 33217477 | 2021 | The RUNX1/RUNX1T1 network: translating insights into therapeutic options. | 83 |
| 35563085 | 2022 | Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia. | 82 |
| 34766123 | 2020 | Modelling t(8;21) acute myeloid leukaemia - What have we learned? | 80 |
| 27798625 | 2016 | The genomic landscape of core-binding factor acute myeloid leukemias. | 79 |
| 37019972 | 2023 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | 71 |
| 33483506 | 2021 | RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia. | 70 |
| 39243082 | 2024 | Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia. | 62 |
| 35902872 | 2022 | RUNX1T1 function in cell fate. | 61 |
| 37841755 | 2023 | CSF3R T618I Collaborates With RUNX1-RUNX1T1 to Expand Hematopoietic Progenitors and Sensitizes to GLI Inhibition. | 61 |
| 20589720 | 2010 | RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1). | 57 |
| 38454121 | 2024 | Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia. | 55 |
| 37790524 | 2023 | Functional Characterization of Cooperating MGA Mutations in RUNX1::RUNX1T1 Acute Myeloid Leukemia. | 55 |
| 35070977 | 2021 | Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. | 52 |
| 35973983 | 2022 | Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. | 52 |
| 37464068 | 2023 | Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo. | 50 |
| 30959925 | 2019 | Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion. | 48 |
| 36442087 | 2022 | Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. | 47 |
| 35326705 | 2022 | CDK6 Degradation Is Counteracted by p16(INK4A) and p18(INK4C) in AML. | 42 |
| 28536267 | 2017 | The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1. | 41 |
| 38427924 | 2024 | Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). | 37 |
| 38017299 | 2024 | Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML. | 37 |
| 33477584 | 2021 | Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1. | 36 |
| 30050054 | 2018 | Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia. | 36 |
| 31899799 | 2020 | Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. | 33 |
| 32115572 | 2020 | ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. | 32 |
| 24783204 | 2014 | RNA sequencing reveals upregulation of RUNX1-RUNX1T1 gene signatures in clear cell renal cell carcinoma. | 32 |
| 35445594 | 2022 | Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions. | 31 |
| 32757686 | 2020 | Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1. | 29 |
| 39154170 | 2024 | Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report. | 29 |
| 28166825 | 2017 | The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. | 28 |
| 31723813 | 2019 | Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations. | 28 |
| 34921223 | 2021 | Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. | 25 |
| 38802593 | 2024 | Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases. | 25 |
| 28395444 | 2017 | [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia]. | 21 |
| 35765876 | 2022 | Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1. | 20 |
| 36833323 | 2023 | Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia. | 20 |
| 38964927 | 2024 | [Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review]. | 20 |
| 39735012 | 2024 | Characterization of Acute Myeloid Leukemia With RUNX1/RUNX1T1 Gene Rearrangement: Clinical, Hematological, and Morphological Features. | 19 |
| 34148054 | 2021 | RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner. | 15 |
| 37621071 | 2023 | Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report. | 15 |
| 38012154 | 2023 | Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study. | 15 |
| 39234860 | 2025 | Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with RUNX1::RUNX1T1. | 15 |
| 35845276 | 2021 | Volunteer unrelated donor cell-derived acute myeloid leukemia with RUNX1-RUNX1T1. | 15 |
| 31856435 | 2019 | [An interlaboratory comparison study on the detection of RUNX1-RUNX1T1 fusion transcript levels and WT1 transcript levels]. | 15 |
| 30623623 | 2019 | Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification. | 13 |
| 36369483 | 2022 | Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. | 11 |
| 38633925 | 2024 | RUNX1::RUNX1T1 Acute Myeloid Leukemia Cytogenetically Showing t(6;8)(p23;q22). | 8 |
| 37519108 | 2023 | Hemophagocytic Lymphohistiocytosis in RUNX1::RUNX1T1 Positive AML with Blast Count Below 20%. | 4 |
| 35502592 | 2022 | Images from the Haematologica Atlas of Hematologic Cytology: acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1. | 1 |
| 37951201 | 2023 | Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1. | 0 |
| 39179670 | 2024 | STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells. | 0 |
| 39191510 | 2024 | WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia. | 0 |
| 36861732 | 2023 | Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. | 0 |
| 30846508 | 2019 | More than a fusion gene: the RUNX1-RUNX1T1 AML. | 0 |
| 29872884 | 2018 | Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1. | 0 |
| 31281149 | 2019 | [Genetic abnormalities in AML]. | 0 |
| 36653696 | 2023 | Comprehensive molecular understanding of pediatric acute myeloid leukemia. | 0 |
| 27770540 | 2017 | A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. | 0 |
| 39264725 | 2024 | Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells. | 0 |
| 19891700 | 2010 | Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse. | 0 |
| 33524443 | 2021 | Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1. | 0 |
| 24616160 | 2014 | Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. | 0 |
| 22032582 | 2011 | Core-binding factor acute myeloid leukemia. | 0 |
| 33782817 | 2021 | Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules. | 0 |
| 17898786 | 2007 | Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. | 0 |
| 34014289 | 2021 | Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML. | 0 |
| 30919505 | 2019 | Measurable residual disease testing for personalized treatment of acute myeloid leukemia. | 0 |
| 24976338 | 2014 | RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells. | 0 |
| 38461410 | 2024 | Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia. | 0 |
| 35900542 | 2022 | Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 - A comprehensive cytogenetic profiling of three cases with review of literature. | 0 |
| 39864466 | 2025 | Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions. | 0 |
| 24327541 | 2014 | The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1. | 0 |
| 35152350 | 2022 | UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8. | 0 |
| 26320575 | 2015 | Decoding of exon splicing patterns in the human RUNX1-RUNX1T1 fusion gene. | 0 |
| 28322996 | 2017 | Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia. | 0 |
| 21325813 | 2011 | Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature. | 0 |
| 26058961 | 2016 | MAPK8-mediated stabilization of SP1 is essential for RUNX1-RUNX1T1 - driven leukaemia. | 0 |
| 33067946 | 2020 | [Clinical Prognostic Factors Analysis of Initially Treated AML Children with t(8;21)/RUNX1-RUNX1T1()]. | 0 |
| 28299658 | 2017 | Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders. | 0 |
| 29472719 | 2018 | Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. | 0 |
| 30569130 | 2019 | Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1‑RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells. | 0 |
| 25348871 | 2015 | Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. | 0 |
| 25635758 | 2015 | Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. | 0 |
| 37024571 | 2023 | Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation. | 0 |
| 38014874 | 2024 | KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1. | 0 |
| 39971668 | 2025 | The Prospective Use of Avapritinib in Relapsed/Refractory (R/R) RUNX1-RUNX1T1-Positive AML Patients With KIT Mutation. | 0 |
| 37102302 | 2023 | TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia. | 0 |
| 29393574 | 2018 | Rare BCR-ABL1 transcript in a RUNX1-RUNX1T1-positive de novo acute myeloid leukemia: The chicken and egg tale. | 0 |
| 29264741 | 2018 | Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21). | 0 |
| 38654658 | 2024 | Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 11921272 | 2002 | 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. | Slovak ML et al |
Summary
Fusion gene
RUNX1/RUNX1T1 RUNX1 (21q22.12) RUNX1T1 (8q21.3) M ins(21;8)(q22;q11q22) ins(21;8)(q22;q12q22) ins(21;8)(q22;q13q22) ins(21;8)(q22;q21q22) ins(21;8)(q22;q22q22) ins(8;21)(q22;q22q22) t(8;21)(q22;q22) t(8;21;14)(q22;q22;q24)|RUNX1/RUNX1T1 RUNX1 (21q22.12) RUNX1T1 (8q21.3) TF LAML|RUNX1/RUNX1T1 RUNX1 (21q22.12) RUNX1T1 (8q21.3) TIC
Note
This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002.
Citation
Jean-Loup Huret
t(8;21)(q22;q22) RUNX1/RUNX1T1 in treatment related leukemia
Atlas Genet Cytogenet Oncol Haematol. 2003-10-01
Online version: http://atlasgeneticsoncology.org/haematological/1293/t(8;21)(q22;q22)-runx1-runx1t1-in-treatment-related-leukemia
